Skip to main content
. 2017 Dec 14;6(12):e007123. doi: 10.1161/JAHA.117.007123

Table 1.

Baseline Characteristics Stratified by Sex for STEMI and NSTEMI

STEMI (N=60 712) NSTEMI (N=119 656)
Women (n=20 140) Men (n=40 572) Difference in Means/Proportions (95% CI)a Women (n=45 254) Men (n=74 402) Difference in Means/Proportions (95% CI)a
Mean (SD) age, y 73.7 (12.2) 66.5 (12.1) −7.22 (−7.43 to −7.02)b 75.6 (11.5) 70.4 (11.9) −5.19 (−5.33 to −5.05)b
Year of hospitalization, n (%)
2003–2005 5903 (29.3) 11 208 (27.6) 1.69 (0.26–3.12)b 13 054 (28.9) 21 099 (28.4) 0.49 (−0.50 to 1.48)
2006–2008 5549 (27.6) 10 911 (26.9) 0.66 (−0.78 to 2.10) 12 704 (28.1) 20 722 (27.9) 0.22 (−0.77 to 1.21)
2009–2011 5263 (26.1) 11 217 (27.7) −1.52 (−3.00 to −0.07)b 11 675 (25.8) 19 448 (26.1) −0.34 (−1.34 to 0.67)
2012–2013 3425 (17.0) 7236 (17.8) −0.82 (−2.36 to 0.72) 7821 (17.3) 13 133 (17.7) −0.37 (−1.43 to 0.69)
Risk factors, n (%)
Diabetes mellitus 3524 (17.5) 5972 (14.7) 2.78 (1.24–4.32)b 10 510 (23.2) 16 384 (22.0) 1.2 (0.17–2.23)b
Hypertension 9724 (48.3) 14 701 (36.2) 12.05 (10.80–13.31)b 24 456 (54.0) 33 436 (44.9) 9.1 (8.28–9.92)b
Current or ex‐smoker 8574 (47.3) 24 075 (63.8) −16.47 (−17.70 to −15.25)b 16 569 (41.2) 42 269 (62.0) −20.78 (21.66 to −19.90)b
Prior cardiovascular diseases, n (%)
Myocardial infarction 2346 (11.7) 5278 (13.0) −1.36 (−2.94 to 0.22) 10 126 (22.4) 19 192 (25.8) −3.42 (−4.44 to −2.40)b
Heart failure 1269 (6.3) 1526 (3.8) 2.54 (0.90–4.18)b 6170 (13.6) 8382 (11.3) 2.36 (1.27–3.45)b
PCI 721 (3.6) 2440 (6.0) −2.43 (−4.08 to −0.78)b 2857 (6.3) 7763 (10.4) −4.12 (−5.24 to −3.00)b
CABG 415 (2.1) 1626 (4.0) −1.95 (−3.62 to −0.28) 2493 (5.5) 8699 (11.7) −6.18 (−7.30 to −5.06)b
Cerebrovascular disease 1775 (8.8) 2746 (6.8) 2.04 (0.42–3.66)b 5335 (11.8) 8189 (11.0) 0.78 (−0.32 to 1.88)
PVD 833 (4.1) 1287 (3.2) 0.97 (−0.69 to 2.63) 3121 (6.9) 5041 (6.8) 0.12 (−1.01 to 1.25)
Other comorbidities, n (%)
Chronic renal failure 372 (1.9) 717 (1.8) 0.08 (−1.60 to 1.76) 1522 (3.4) 2991 (4.0) −0.66 (−1.81 to −0.49)
COPD 1358 (6.7) 1656 (4.1) 2.66 (1.02–4.30)b 4130 (9.1) 5208 (7.0) 2.13 (1.01–3.25)b
Presentation characteristics
Systolic BP, mm Hg, mean (SD) 140.0 (31.4) 140.9 (29.6) 0.87 (0.32–1.43)b 150.4 (30.8) 148.5 (28.6) −1.83 (−2.21 to −1.46)b
Systolic BP, ≤90 mm Hg, n (%) 1032 (5.1) 1555 (3.8) 1.29 (−0.36 to 2.94) 924 (2.0) 1323 (1.8) 0.26 (−0.90 to 1.42)
Heart rate, beats/min, mean (SD) 79.7 (22.4) 76.8 (21.0) −2.87 (−3.26 to −2.47)b 86.5 (24.5) 81.3 (23.9) −5.24 (−5.54 to −4.93)b
Heart rate, >110 beats/min, n (%) 1430 (8.4) 2068 (6.0) 2.39 (0.63–4.15)b 5521 (14.4) 6380 (10.1) 4.31 (3.13–5.49)b
ST‐segment deviation, n (%) 18 841 (93.8) 37 909 (93.8) 0 (−0.42 to 0.42) 16 852 (37.9) 26 483 (36.3) 1.64 (0.71–2.57)b
In‐hospital course, n (%)
Cardiac arrest 1265 (6.3) 2491 (6.1) 0.14 (−1.50 to 1.78) 961 (2.1) 1878 (2.5) −0.41 (−1.56 to 0.74)
Use of a loop diuretic 5703 (28.5) 8181 (20.3) 8.23 (6.77–9.70)b 13 511 (30.0) 16 177 (21.9) 8.15 (7.15–9.15)b
Reperfusion 13 768 (68.5) 32 093 (79.2) −10.7 (−11.60 to −9.81)b NA NA NA
Revascularization 13 023 (64.7) 32 446 (80.0) −15.31 (−16.24 to −14.38)b 14 528 (32.1) 37 616 (50.6) −18.46 (−19.37 to −17.55)b
Treatments at discharge
Aspirin 17 304 (87.1) 36 873 (91.8) −4.66 (−5.23 to −4.09)b 38 451 (85.7) 65 956 (89.4) −3.68 (−4.10 to −3.26)b
β‐Blocker 16 530 (83.1) 35 417 (88.0) −4.89 (−5.55 to −4.23)b 37 535 (83.6) 63 518 (86.0) −2.37 (−2.83 to −1.91)b
Statin 14 612 (73.5) 34 431 (85.6) −12.12 (−12.93 to −11.31)b 30 419 (67.8) 58 677 (79.5) −11.68 (−12.30 to −11.06)b
ACEi or ARB 13 070 (70.3) 29 372 (77.7) −7.35 (−8.27 to −6.43)b 27 271 (65.3) 47 912 (69.4) −4.15 (−4.85 to −3.45)b
P2Y12 inhibitor 14 176 (71.2) 32 519 (80.8) −9.56 (−10.42 to −8.70)b 26 329 (58.6) 49 396 (66.8) −8.23 (−8.96 to −7.50)b

Difference in means for continuous variables and proportions for categorical variables. Reperfusion comprises fibrinolysis or primary PCI. Revascularization comprises PCI or CABG surgery. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; NSTEMI indicates non–ST‐segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST‐segment–elevation myocardial infarction.

a

significance level of p value <0.05..

b

Significance level <0.05.